Related Experiment Video
Updated: May 6, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
[Expression and significance of MMP-26, TIMP-4 and MMP-9 in diffuse large B-cell lymphoma cells]
Yong-Huai Feng1, Liu-Song Wu, Jun Su
1Department of Hematology, The First Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou Province, China.
Abstract:
The aim of this study was to investigate the expression of matrix metalloproteinase 26 (MMP-26), tissue inhibitor of metalloproteinase-4 (TIMP-4) and matrix metalloproteinase 9 (MMP-9) in patients with diffuse large B cell lymphoma (DLBCL) and their correlations with pathogenesis and development of DLBCL. A total of 95 specimens excised from DLBCL patients were prepared. Expression of MMP-26, TIMP-4 and MMP-9 were tested by SABC immunohistochemistry method and its correlation to clinicopathology indexes were analyzed. The results showed that as compared with reactive hyperplasia of lymph nodes, the high expression of MMP-26, TIMP-4 and MMP-9 were found in different types of DLBCL. The positive expression rate of MMP-26 was related to immune typing (P < 0.05). The expression level of MMP-26 in GCB was lower than that in non-GCB, and did not relate to clinical staging, age, sex, diseased region (P > 0.05). The positive expression rate of MMP-9 was related to clinical staging, the positive expression rate of MMP-9 proteins in patient at III and IV stage was obviously higher than that in patients at I and II stage, but did not relate to immune type, age, sex and diseased region of DLBCL (P > 0.05). The expression of TIMP-4 did not relate to immune type, clinical stage, age, sex, disease region (P > 0.05). The expression of MMP-26 in pathologic tissue of DLBCL did not relate to expression of TIMP-4, but positively related to expression of MMP-9 protein (r = 0.486, P < 0.05). It is concluded that MMP-26 and MMP-9 synergically express in DLBCL. MMP-26 may be involve in pathogenesis and invasiveness of DLBCL, the expression of MMP-26 relates to subtypes of DLBCL. The MMP-26 may serve as an indicator for typing of DLBCL and contributes to predict the invasion and metastasis of DLBCL and itself may become a potential target for therapy.
Insights
Matrix metalloproteinase-26 (MMP-26) and MMP-9 are highly expressed in diffuse large B cell lymphoma (DLBCL) and correlate with disease subtypes and stage. MMP-26 may indicate DLBCL typing and predict invasion.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Context:
- Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Understanding the molecular mechanisms driving DLBCL pathogenesis and progression is crucial for developing targeted therapies.
Purpose:
- To investigate the expression of matrix metalloproteinase 26 (MMP-26), tissue inhibitor of metalloproteinase-4 (TIMP-4), and matrix metalloproteinase 9 (MMP-9) in DLBCL.
- To correlate their expression with clinicopathological features and pathogenesis of DLBCL.
Summary:
- High expression of MMP-26, TIMP-4, and MMP-9 was observed in DLBCL compared to reactive lymph nodes.
- MMP-26 expression correlated with DLBCL immune typing (GCB vs. non-GCB) and MMP-9 expression.
- MMP-9 expression was associated with advanced clinical stage (III/IV). TIMP-4 expression showed no significant correlation with clinicopathological factors.
Impact:
- MMP-26 and MMP-9 may synergistically contribute to DLBCL pathogenesis and invasiveness.
- MMP-26 expression could serve as a potential biomarker for DLBCL subtyping and predicting invasion/metastasis.
- These findings suggest MMP-26 as a potential therapeutic target for DLBCL.
Related Concept Videos
01:23Role of Matrix Metalloproteases in Degradation of ECM
02:23Abnormal Proliferation